西利|CCR：早发现这个标志物，就知道为啥有些ER+乳腺癌用不对药了！( 二 ) 研究|基线|患者|et|癌细胞|标志

因此，总的来说，这些结果都表明，高CCNE1水平可能是内分泌治疗+CDK4/6抑制剂反应差的预测标志物。这有助于在之后的临床试验和临床治疗中帮助筛选更有可能从治疗中获益的患者群体。
参考文献：
[1] Howlader N, Altekruse S F, Li C I, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status[J]. JNCI: Journal of the National Cancer Institute, 2014, 106(5).
[2] Dowsett M, Kilburn L, Rimawi M F, et al. Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2-breast cancer[J]. Clinical Cancer Research, 2021.
[3] Johnston S, Puhalla S, Wheatley D, et al. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial[J]. 2019.
[6] Turner N C, Liu Y, Zhu Z, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor–positive metastatic breast cancer[J]. Journal of Clinical Oncology, 2019, 37(14): 1169-1178.
【西利|CCR：早发现这个标志物，就知道为啥有些ER+乳腺癌用不对药了！】[7] Prat A, Chaudhury A, Solovieff N, et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies[J]. Journal of Clinical Oncology, 2021, 39(13): 1458-1467.